Evidence map›Paper›PMID 29145971›Full record

ReviewDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2017

Antimicrobial blue light inactivation of pathogenic microbes: State of the art.

Yucheng Wang, Ying Wang, Yuguang Wang, Clinton K Murray, Michael R Hamblin, David C Hooper, Tianhong Dai

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05739058 nacompletednot on this mapstarted 2023, after this paper: background citation

Violet-Blue Light Inactivation of Bacteria in Chronic Wounds

TypeinterventionalSponsorBispebjerg HospitalRan2023 to 2024Enrolled22ConditionsPhototherapy Complication, Photobiology, Light Treatment, ComplicationsArmsViolet-Blue Light Treatment / FlashHeal Device
NCT07275827 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection

TypeinterventionalSponsorTanta UniversityRan2026 to 2026Enrolled88ConditionsHELICOBACTER PYLORI INFECTIONSArmszinc sulfate, Vonoprazan + amoxicillin + clarithromycin, proton pump inhibitor + amoxicillin
3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 283 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Microbiology spectrum · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Base-Catalyzed Pathway Towards Isocyanate Derivatives of Silsesquioxanes.International journal of molecular sciences · 2025
    Article
  15. Article
  16. Article
  17. Evaluation of 415-nm Blue Light and Hypochlorous Acid on the Rhesus Macaque (Macaca mulatta) Cranial Implant Microbiota.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025
    Article
  18. Low-Irradiance Antimicrobial Blue Light-Bathing Therapy for Wound Infection Control.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  19. Observational
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yucheng WangWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Cancer Center, Aviation General Hospital, Beijing, China; Department of Medical Oncology, Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing, China.
Ying WangWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Laser Medicine, Chinese PLA General Hospital, Beijing, China.
Yuguang WangWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center of Digital Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.
Clinton K MurrayInfectious Disease Service, San Antonio Military Medical Center, JBSA-Fort Sam Houston, TX, USA.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
David C HooperDivision of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tianhong DaiWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: tdai@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · USSan Antonio Military Medical Center · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Antimicrobial blue light inactivation of pathogenic microbesR01AI123312 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI DAI, TIANHONG · 2016 to 2020
$2.6M
Blue light for drug resistant skin and soft tissue infectionsR21AI109172 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI DAI, TIANHONG · 2014 to 2015
$473k
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R01 AI123312NIAID NIH HHS R21 AI109172NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

As an innovative non-antibiotic approach, antimicrobial blue light in the spectrum of 400-470nm has demonstrated its intrinsic antimicrobial properties resulting from the presence of endogenous photosensitizing chromophores in pathogenic microbes and, subsequently, its promise as a counteracter of antibiotic resistance. Since we published our last review of antimicrobial blue light in 2012, there have been a substantial number of new studies reported in this area. Here we provide an updated overview of the findings from the new studies over the past 5 years, including the efficacy of antimicrobial blue light inactivation of different microbes, its mechanism of action, synergism of antimicrobial blue light with other angents, its effect on host cells and tissues, the potential development of resistance to antimicrobial blue light by microbes, and a novel interstitial delivery approach of antimicrobial blue light. The potential new applications of antimicrobial blue light are also discussed.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsDrug Resistance, BacterialFungiHumansLightMicrobial Sensitivity TestsMycosesPhototherapyTreatment OutcomeAnti-Bacterial AgentsAntibiotic resistanceAntimicrobial blue lightBacteriumEndogenous photosensitizerFungusInfectionMicrobeNon-antibiotic approach

Identifiers

PMID29145971
PMCPMC5699711
OpenAlexW2763460230

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.